FilingReader Intelligence
Jubilant Pharmova reports 48% profit surge in Q1
July 29, 2025 at 08:19 AM UTC•By FilingReader AI
Jubilant Pharmova reported Q1 FY26 revenue of INR 1,901 crore, up 10% year-on-year, with EBITDA rising 14% to INR 302 crore. Normalised profit after tax surged 48% to INR 103 crore.
Key drivers included strong performance in Radiopharma and CRDMO divisions, plus 14% revenue growth in CDMO Sterile Injectables to INR 370 crore.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:JUBLPHARMA•Bombay Stock Exchange
News Alerts
Get instant email alerts when JUBILANT PHARMOVA publishes news
Free account required • Unsubscribe anytime